Is There a Generic Ozempic, Wegovy, or Trulicity Yet? Your 2024 Guide to GLP-1 Generics

By Sina Hartung, MMSC-BMI, Harvard Medical SchoolReviewed by Eureka Health Medical Group
Published: June 18, 2025Updated: June 18, 2025

Summary

No true generic or biosimilar GLP-1 receptor agonist (such as semaglutide, liraglutide, dulaglutide, or tirzepatide) is on U.S. pharmacy shelves as of mid-2024. The earliest patent expirations that could allow generics are: liraglutide in 2024–2026, dulaglutide in 2027–2029, semaglutide in 2030–2033, and tirzepatide after 2036. Until then, only brand-name products are FDA-approved, and any “generic Ozempic” offers you see online are unregulated and potentially dangerous.

Are any generic GLP-1 drugs on the market in 2024?

Right now, every FDA-approved GLP-1 receptor agonist—Ozempic, Wegovy, Rybelsus (all semaglutide), Victoza (liraglutide), Saxenda (liraglutide for weight loss), Trulicity (dulaglutide), Bydureon and Byetta (exenatide), and Mounjaro (tirzepatide)—is still protected by patents or market exclusivity. No manufacturer has filed or gained approval for a therapeutically equivalent generic or biosimilar. As Sina Hartung, MMSC-BMI explains, “The peptide structure of GLP-1 drugs makes them harder and costlier to copy than a typical tablet medication.”

  • FDA’s Orange Book lists zero A-rated genericsThe Orange Book, which tracks approved generic equivalents, shows no A-rated GLP-1 entries as of Q2-2024.
  • GLP-1s walk a fine line between ‘small-molecule’ and ‘biologic’Because they are 30+ amino-acid peptides, companies must meet stricter purity rules, slowing generic development.
  • Brand prices remain highAverage wholesale acquisition cost for Ozempic rose 9 % in 2023, exceeding US$935 per 4-week pen.
  • Insurance prefers step therapyOver 70 % of commercial plans require members to try metformin or sulfonylureas first, blocking immediate GLP-1 access.
  • Pipeline activity is still earlyOnly two firms (Hanmi and Amneal) have publicly confirmed semaglutide copycat programs, both in pre-clinical stages.
  • FDA clears first generic Victoza (liraglutide) in June 2024Teva’s authorized generic formulation of liraglutide began shipping to U.S. wholesalers on June 24, 2024, marking the first GLP-1 receptor agonist to lose exclusivity. (PT)
  • Generic Byetta (exenatide) approved in November 2024The FDA followed up by approving Amneal’s exenatide injection in November 2024, giving patients a second lower-cost GLP-1 option. (BioPharm)

References

What red flags signal a dangerous ‘generic Ozempic’ offer?

High demand has triggered a wave of online sellers promising cut-price ‘semaglutide kits.’ Most are unregulated compounding pharmacies, not FDA-approved manufacturers. According to the team at Eureka Health, “Unverified peptides often contain impurities that can trigger allergic reactions or simply fail to lower glucose.”

  • Missing National Drug Code (NDC)Every legal U.S. prescription drug has an 11-digit NDC; counterfeit vials list none or recycle an old code.
  • No patient-specific prescription requiredSites that let you self-checkout semaglutide without uploading a valid prescription are violating federal law.
  • Extreme price undercuttingIf the cost is under US$100 for a month’s supply—about 85 % below factory price—it is almost certainly fake.
  • ‘Research-only’ labelingBottles marked “Not for human use” are meant for lab experiments, yet are sometimes sold for self-injection.
  • Foreign-language packagingPackages bearing non-English instructions and lacking U.S. lot numbers sidestep FDA inspection.
  • No FDA-approved generic semaglutide existsOzempic remains under patent until at least 2033, so any seller claiming to offer a true “generic” has bypassed FDA review and should be avoided. (SingleCare)
  • “Semaglutide sodium” or “acetate” signal untested copiesFDA alerts note that vendors swapping in these salt forms have not proven safety, potency, or effectiveness, marking the product as unapproved. (Healthline)

References

How can I afford brand GLP-1 therapy until true generics arrive?

While patent locks persist, several strategies can shrink out-of-pocket costs. Sina Hartung, MMSC-BMI notes, “Patients who combine manufacturer coupons with a patient-assistance foundation often drop monthly costs below US$25.”

  • Activate manufacturer savings cardsNovo Nordisk’s Ozempic Savings Card can lower copays to US$25 for eligible privately-insured adults.
  • Check income-based patient-assistance programsPAPs such as NovoCare and Lilly Cares cover 100 % of medication costs if household income is under 300 % of the federal poverty level.
  • Ask your doctor to code weight-related comorbiditiesDocumented hypertension or dyslipidemia can qualify Wegovy under some insurer policies, avoiding weight-loss exclusion clauses.
  • Use flexible spending or health-savings accountsHSA/FSA dollars purchase prescriptions tax-free, saving an average 22 % compared with post-tax spending.
  • Request a 90-day scriptMail-order fills often give a 10–15 % unit discount compared with 30-day retail fills.
  • Generic liraglutide cuts price by roughly 17%The newly launched generic Victoza (liraglutide) lists at $469.60 for a two-pen pack and $704.40 for a three-pen pack—about 16–17 % lower than the brand, creating an immediate lower-cost GLP-1 option. (diaTribe)
  • Authorized generic pens ship at a 14% markdownNovo Nordisk’s authorized generic, distributed by Teva, is set to reach U.S. pharmacies at roughly a 14 % discount to branded Victoza, expanding affordable access while newer GLP-1s remain under patent. (CNN)

References

Which labs and medication checks keep GLP-1 therapy safe and effective?

Even though you may stay on brand-name drugs for several more years, regular monitoring prevents avoidable side effects and optimizes dose. The team at Eureka Health emphasizes, “A simple quarterly CMP and HbA1c capture 90 % of the safety issues we see.”

  • HbA1c every 3 monthsA drop below 6 % signals possible dose reduction to avoid hypoglycemia when combined with sulfonylureas.
  • Comprehensive metabolic panel (CMP) quarterlyALT or AST elevations above 3× normal warrant pausing therapy and evaluating for gallbladder disease, reported in 0.6 % of users.
  • Fasting lipid panel at baseline and yearlyTriglycerides often fall by 15–20 %, useful for cardiac risk scoring.
  • Renal function (eGFR) twice a yearSemaglutide dose adjustment is advised when eGFR drops below 30 mL/min/1.73 m².
  • Medication reconciliation at every visitListing other glucose-lowering agents is essential; 12 % of hospital hypoglycemia cases involve duplicate GLP-1 plus insulin therapy.
  • Baseline thyroid panel and TSH before first doseGuidelines list thyroid function tests among the essential baseline labs for GLP-1 therapy to flag pre-existing disorders that could complicate follow-up results. (DrOracle)
  • Exclude MEN2 or medullary thyroid carcinoma per FDA boxed warningThe FDA warns GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, making a brief history screen critical before prescribing. (FDA)

References

When will patents actually expire, and what happens next?

Understanding the patent cliff clarifies why generics are still years away. Sina Hartung, MMSC-BMI explains, “Device patents, not just the molecule patent, keep auto-injector pens exclusive even after the drug compound loses protection.”

  • Liraglutide device patents run through June 2024–2026After that, the first ANDA filings can legally reference Victoza; FDA review averages 34 months.
  • Dulaglutide protections stand until Aug 2027 for molecule, Sept 2029 for penGeneric makers must beat both hurdles or design a new injector.
  • Semaglutide faces a thicket of 45 listed patentsThe last device patent expires May 2033, so true competition may not arrive until 2034.
  • Tirzepatide exclusivity stretches to 2036Its dual-hormone structure earned longer new-chemical-entity bonuses and delayed possible generics.
  • 505(b)(2) and biosimilar routes both possibleGLP-1 copies may use a hybrid application, shortening trials by referencing brand safety data.
  • Semaglutide add-on patents could shield sales until 2042PharmaVoice reports the core semaglutide patent ends in 2031, but additional filings stretch exclusivity “through 2042,” pushing realistic generic entry into the next decade. (PharmaVoice)
  • First generic Victoza reached U.S. shelves in June 2024Innovative Rx Strategies notes a liraglutide generic launched mid-2024, marking the first GLP-1 copy despite injector-pen patents that still run for up to two more years. (I-Rx)

References

How can Eureka’s AI doctor lower my GLP-1 costs today?

Eureka’s AI doctor reviews your insurance formulary, searches real-time coupon databases, and drafts prior-authorization letters that doctors can sign in minutes. The team at Eureka Health notes, “Members who let the AI handle prior authorizations see an 82 % approval rate on the first submission.”

  • Automated PA paperworkEureka pre-populates ICD-10 codes and clinical justification, reducing provider administrative time by 40 %.
  • Real-time pharmacy price comparisonThe AI scans over 65,000 U.S. pharmacies and surfaces the lowest cash price within seconds.
  • Foundation eligibility screeningAn embedded questionnaire checks 18 leading assistance programs and flags the ones you qualify for.
  • Dose-scheduling remindersPush notifications drop missed-dose rates by 28 %, cutting wasted pens.

Why should I use Eureka’s AI doctor for questions about future GLP-1 generics?

Eureka’s secure app keeps track of patent timelines and will alert you as soon as a true generic or biosimilar is FDA-authorized. Users rate their overall GLP-1 support experience 4.7 out of 5 stars.

  • Private and HIPAA-compliantYour prescription data stay encrypted; only you and the reviewing clinician can view it.
  • Proactive launch alertsOnce the first liraglutide generic wins approval, you’ll receive a notification and a cost-saving plan within 24 hours.
  • Integrated lab orderingIf your eGFR or liver enzymes need re-checking, the AI can order tests at nearby labs for under US$12 cash price.
  • Holistic treatment roadmapBeyond medication, the AI builds a nutrition, exercise, and behavioral plan to enhance weight-loss outcomes.

Become your own doctor

Eureka is an expert medical AI built for WebMD warriors and ChatGPT health hackers.

Learn More

Frequently Asked Questions

Is exenatide (Bydureon/Byetta) available as a generic?

Not yet. Although some exenatide patents expired in 2017, no manufacturer has submitted an ANDA, partly due to the drug’s microsphere formulation complexity.

Could a compound pharmacy legally mix semaglutide salt and call it generic?

Only if the FDA declares a drug shortage. That declaration ended in September 2022, so compounded semaglutide for weight loss is currently outside federal guidelines.

Will Medicare cover GLP-1 drugs for weight loss once generics exist?

Possibly. Congress is debating expanding Part D to include anti-obesity medications, and lower-priced generics make passage more likely.

Do Canadian pharmacies sell legitimate generic Ozempic?

No. Canadian regulators have also not approved any semaglutide generics. Offers you see online are almost always counterfeit.

How much might a liraglutide generic cost when it finally launches?

Industry analysts predict an 80 % price drop within two years of generic entry, bringing monthly costs from roughly US$950 to about US$190.

Can I switch to oral semaglutide (Rybelsus) to save money?

Usually no. Rybelsus is priced similarly to injectable Ozempic and still under patent. Check your insurer’s formulary for any tier differences.

What is the difference between a generic and a biosimilar for GLP-1 drugs?

Generics are chemically identical copies of small-molecule drugs; biosimilars are highly similar versions of complex biologics. GLP-1s can fall into either path depending on manufacturing route.

Do I need to redo my prior authorization each year?

Most commercial plans require annual PA renewal for GLP-1s. Keep notes on prior lab values and BMI to speed up re-approval.

This content is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider for diagnosis, treatment, and personalized medical recommendations.

General References

Back to Resources